News
Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound Eli Lilly's stock wobbled Thursday after a looming coverage hit ...
Eli Lilly said that it planned to seek regulatory approval to market the drug for weight loss later this year, and early next year for diabetes. The F.DA. could take months and possibly longer ...
Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.
Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C ...
But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...
Eli Lilly shares jumped ... s clinical trial registry, Lilly’s primary obesity trial is not expected to conclude until at least July. An oral version of weight loss drugs could pose a threat ...
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...
Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback